1. 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials. (April 2018) Authors: Lerebours, F.; Pulido, M.; Fourme, E.; Debled, M.; Becette, V.; Bonnefoi, H.; Rivera, S.; Mac Grogan, G.; Mouret-Reynier, M.A.; Tunon de Lara, C.; Pierga, J.Y.; Breton-Callu, C.; Venat-Bouvet, L.; Mathoulin-Pelissier, S.; Kerbrat, P.; Dalenc, F.; Sigal, B.; Bachelot, T.; Lemonnier, J.; Lerebours, Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-0594 Acute toxicity results after breast-conserving therapy in "boost vs no boost (BONBIS)" DCIS trial. (April 2019) Authors: Bourgier, C.; Cowen, D.; Lemanski, C.; Castan, F.; Rivera, S.; De La Lande, B.; Peignaux, K.; Le Blanc-Onfroy, M.; Benyoucef, A.; Mege, A.; Douadi-Gaci, Z.; Racadot, S.; Latorzeff, I.; Schick, U.; Jacquot, S.; Massabeau, C.; Guilbert, P.; Geffrelot, J.; Ellis, S.; Lecouillard, I. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗